Telehealth clinics that prescribe a Schedule III dissociative anesthetic for depression, mood disorders, or chronic pain sit at the intersection of three separate enforcement regimes. The Drug Enforcement Administration regulates how the prescription can be issued over video. The Food and Drug Administration has approved only one derivative of the drug class for a psychiatric indication; a virtual clinic dispensing anything else is prescribing off-label. State medical boards scrutinize whether a video visit can support the diagnosis at all. Any one of these facts invites a federal subpoena or a board inquiry. Together, they turn a single prescription into exposure under three different regulators at once.
DEA Telemedicine Rules for Controlled-Substance Prescribing
The Ryan Haight Online Pharmacy Consumer Protection Act generally requires a prescribing practitioner to conduct at least one in-person medical evaluation of a patient before issuing a prescription for a controlled substance by telemedicine, subject to a short list of statutory exceptions. The Drug Enforcement Administration and the Department of Health and Human Services have kept that in-person requirement suspended through a series of temporary rules since the COVID-19 public health emergency. The current version, a fourth temporary extension, keeps the flexibility in place only through December 31, 2026. A permanent special registration framework has been proposed but has not been finalized. A telehealth clinic built entirely on the temporary exception has no fallback plan if the exception lapses or narrows.
December 31, 2026 is written into a temporary federal rule, not a permanent right, and a telehealth clinic with no in-person contingency plan has no fallback when that date arrives.
FDA-Approved Forms Versus Compounded Use
The Food and Drug Administration has approved exactly one version of this drug class for a psychiatric indication: esketamine, sold under the brand name Spravato, a nasal spray approved for treatment-resistant depression and for depressive symptoms in major depressive disorder with acute suicidal ideation. Spravato can only be administered under direct observation at a healthcare setting certified under its Risk Evaluation and Mitigation Strategy, with monitoring for at least two hours after each dose. The FDA has said the underlying anesthetic itself is not approved for any psychiatric use, and the agency has warned health care professionals about compounded versions since 2022. On June 23, 2026, FDA sent warning letters to multiple online sellers for distributing unapproved and misbranded versions of the drug, some marketed as take-home oral troches with no clinical monitoring at all. A telehealth clinic that mails a compounded, unsupervised version to a patient's home is operating entirely outside the one pathway FDA has approved.
Why Virtual Clinics Draw Medical Board and Audit Attention
Medical boards and federal investigators ask the same basic question a malpractice case would ask: did the visit actually support the diagnosis and the prescription? A telehealth encounter built on an intake questionnaire alone, without a documented medical history, identity verification, or a plan for monitoring a dissociative drug's known cardiovascular and psychiatric effects, is the fact pattern our guide to establishing the provider-patient relationship by telehealth identifies as the one that draws board scrutiny and, in serious cases, federal charges. Consent also has to be documented for each visit, not just at intake, because a payor or program-integrity audit can treat an undocumented visit as unsupported regardless of what was actually discussed. Marketing-driven clinics that pay prescribers or affiliates based on prescription volume add a further layer of exposure; our review of DTC telehealth enforcement covers how that compensation structure draws the same federal attention regardless of which controlled substance is involved.
Why Early Legal Counsel Is Critical
It is critical that telehealth providers promptly retain experienced healthcare defense counsel upon receiving a subpoena, a DEA inquiry, a medical board complaint, or any other government inquiry tied to controlled-substance prescribing. Early legal intervention can protect the provider's rights, ensure appropriate responses to government requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to risk that proper handling could have avoided.
How Health Law Alliance Can Help
Health Law Alliance represents telehealth providers, physicians, and healthcare companies in DEA, FDA, and medical board matters tied to controlled-substance prescribing, working with our telehealth and telemedicine defense team from the first inquiry through any board hearing or federal investigation.
Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience.
If a telehealth clinic has received a DEA inquiry, a medical board complaint, or an FDA warning letter tied to controlled-substance prescribing, contact Health Law Alliance's telehealth and telemedicine defense team for a free, confidential consultation.
